Literature DB >> 33777788

E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.

Jin Li1, Wei Zhang1, Jian Gao1, Min Du1, Huimin Li1, Mengge Li1,2, Hui Cong1, Yuan Fang3, Yiyi Liang1, Dan Zhao1, Gang Xiang4, Xiaojing Ma4, Ming Yao1, Hong Tu1, Yu Gan1.   

Abstract

The ubiquitin-proteasome system (UPS) is a regulated mechanism of intracellular protein degradation and turnover, and its dysfunction is associated with various diseases including cancer. UBR5, an E3 ubiquitin ligase, is emerging as an important regulator of the UPS in cancers, but its role in pancreatic cancer is poorly understood. Here, we show that UBR5 is significantly upregulated in pancreatic cancer tissues. High UBR5 expression is correlated with increased lymph node metastasis and poor survival of patients. The loss-of-function and gain-of-function studies demonstrated that UBR5 substantially enhanced the in vitro migratory and invasive ability of pancreatic cancer cells. UBR5 knockdown also markedly inhibited in vivo cancer metastasis in the liver metastatic model of pancreatic cancer in nude mice, suggesting UBR5 as a potent metastatic promoter in pancreatic cancer. Furthermore, using co-immunoprecipitation combined with mass spectrometry analyses, CAPZA1, a member of F-actin capping protein α subunit family, was identified as a novel substrate of UBR5. UBR5 overexpression could promote the degradation of CAPZA1 via the UPS and induce the accumulation of F-actin, which has been described as an essential molecular event during the process of CAPZA1 deficiency-induced cancer cells migration and invasion. UBR5 knockdown significantly increased the intracellular level of CAPZA1 and CAPZA1 downregulation largely reversed the UBR5 knockdown-induced suppression of cell migration and invasion in pancreatic cancer cells. Collectively, our findings unveil UBR5 as a novel and critical regulator of pancreatic cancer metastasis and highlight the potential for UBR5-CAPZA1 axis as a therapeutic target for preventing metastasis in pancreatic cancer patients, especially in those with increased UBR5 expression.
Copyright © 2021 Li, Zhang, Gao, Du, Li, Li, Cong, Fang, Liang, Zhao, Xiang, Ma, Yao, Tu and Gan.

Entities:  

Keywords:  CAPZA1; UBR5; metastasis; pancreatic cancer; ubiquitination

Year:  2021        PMID: 33777788      PMCID: PMC7994773          DOI: 10.3389/fonc.2021.634167

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  40 in total

Review 1.  Protein degradation and protection against misfolded or damaged proteins.

Authors:  Alfred L Goldberg
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

Review 2.  Preclinical models of pancreatic ductal adenocarcinoma.

Authors:  Benjamin D Krempley; Kenneth H Yu
Journal:  Chin Clin Oncol       Date:  2017-06

3.  Overexpression of UBR5 promotes tumor growth in gallbladder cancer via PTEN/PI3K/Akt signal pathway.

Authors:  Zhen Zhang; Xin Zheng; Jiaxin Li; Jutao Duan; Lihua Cui; Lei Yang; Lanqiu Zhang; Qi Zhang; Ximo Wang
Journal:  J Cell Biochem       Date:  2019-02-18       Impact factor: 4.429

Review 4.  Early Detection of Pancreatic Cancer: Opportunities and Challenges.

Authors:  Aatur D Singhi; Eugene J Koay; Suresh T Chari; Anirban Maitra
Journal:  Gastroenterology       Date:  2019-02-02       Impact factor: 22.682

5.  UBR5 Contributes to Colorectal Cancer Progression by Destabilizing the Tumor Suppressor ECRG4.

Authors:  Jin Wang; Xiaomu Zhao; Lan Jin; Guocong Wu; Yingchi Yang
Journal:  Dig Dis Sci       Date:  2017-08-30       Impact factor: 3.199

6.  PDLIM1 Inhibits Tumor Metastasis Through Activating Hippo Signaling in Hepatocellular Carcinoma.

Authors:  Zhao Huang; Jian-Kang Zhou; Kui Wang; Haining Chen; Siyuan Qin; Jiayang Liu; Maochao Luo; Yan Chen; Jingwen Jiang; Li Zhou; Lei Zhu; Juan He; Jiao Li; Wenchen Pu; Yanqiu Gong; Jianbo Li; Qin Ye; Dandan Dong; Hongbo Hu; Zongguang Zhou; Lunzhi Dai; Canhua Huang; Xiawei Wei; Yong Peng
Journal:  Hepatology       Date:  2020-01-21       Impact factor: 17.425

7.  Glycogen synthase kinase (GSK) 3β phosphorylates and protects nuclear myosin 1c from proteasome-mediated degradation to activate rDNA transcription in early G1 cells.

Authors:  Aishe A Sarshad; Martin Corcoran; Bader Al-Muzzaini; Laura Borgonovo-Brandter; Anne Von Euler; Douglas Lamont; Neus Visa; Piergiorgio Percipalle
Journal:  PLoS Genet       Date:  2014-06-05       Impact factor: 5.917

Review 8.  Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.

Authors:  Aleksandra Adamska; Alice Domenichini; Marco Falasca
Journal:  Int J Mol Sci       Date:  2017-06-22       Impact factor: 5.923

9.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.

Authors:  Zefang Tang; Chenwei Li; Boxi Kang; Ge Gao; Cheng Li; Zemin Zhang
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

10.  E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα.

Authors:  Leifeng Chen; Rongfa Yuan; Chongyu Wen; Tiande Liu; Qian Feng; Xueqiang Deng; Yunyan Du; Xiaogang Peng
Journal:  Oncogene       Date:  2020-10-29       Impact factor: 9.867

View more
  3 in total

1.  BoxCar and shotgun proteomic analyses reveal molecular networks regulated by UBR5 in prostate cancer.

Authors:  Yiwu Yan; Bo Zhou; Yeon-Joo Lee; Sungyong You; Michael R Freeman; Wei Yang
Journal:  Proteomics       Date:  2021-12-23       Impact factor: 3.984

2.  UBR5 is a novel regulator of WNK1 stability.

Authors:  Ji-Ung Jung; Anwesha B Ghosh; Svetlana Earnest; Staci L Deaton; Melanie H Cobb
Journal:  Am J Physiol Cell Physiol       Date:  2022-04-20       Impact factor: 5.282

3.  SIAH1-mediated RPS3 ubiquitination contributes to chemosensitivity in epithelial ovarian cancer.

Authors:  Lu Chen; Wujiang Gao; Chunli Sha; Meiling Yang; Li Lin; Taoqiong Li; Hong Wei; Qi Chen; Jie Xing; Mengxue Zhang; Shijie Zhao; Wenlin Xu; Yuefeng Li; Xiaolan Zhu
Journal:  Aging (Albany NY)       Date:  2022-08-08       Impact factor: 5.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.